Avidity Biosciences Inc

-0.43 (-3.43%)
4:00:10 PM EDT: $12.10 0.00 (0.00%)

Avidity Biosciences Announces FDA Partial Clinical Hold On New Participant Enrollment In Phase 1/2 Marina Trial

Published: 09/27/2022 11:55 GMT
Avidity Biosciences Inc (RNA) - Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 Marina™ Trial.
Avidity Biosciences Inc - Participants Currently Enrolled in Marina and Marina-ole Trials May Continue to Be Treated With Aoc 1001.
Avidity Biosciences - Received Investigational New Drug Clearance for Fshd and Dmd Studies From FDA; Programs Now Advancing Into Clinic.
Avidity Biosciences Inc - All Participants in Marina May Roll Over Into Marina-ole Where They Will Receive Aoc 1001 As Planned.
Avidity Biosciences - Partial Clinical Hold is in Response to a Serious Adverse Event Reported in a Single Participant in 4mg/kg Cohort of Marina Study.
Avidity Biosciences - Working Closely With FDA and Trial Investigator to Assess Cause of Serious Adverse Event.
Avidity - on Track to Conduct Preliminary Assessment of Safety, Tolerability, Key Biomarkers in About Half of Study Participants in Marina Trial in Q4 2022.